What is ABEO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.28B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ABEO?

P/E (TTM) is n/a and 52-week range is $4.00 to $7.65 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ABEO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ABEO?

The company profile lists revenue (TTM) near $25M, net income (TTM) near $-5.77B, EPS (TTM) near $-1.12 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Abeona Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cleveland, Ohio, US, 57M shares outstanding, ISIN US00289Y2063 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Abeona Therapeutics Inc

$ABEO

Health Care · Biotechnology

IR Run Scenarios

$4.94

-0.40%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in Cleveland, Ohio and currently employs 226 full-time employees. The firm's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).

Employees

226

Website

abeonatherapeutics.com/

IPO

1980-09-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)